{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T06:46:30Z","timestamp":1785825990442,"version":"3.56.0"},"reference-count":90,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100023674","name":"Deanship of Scientific Research, King Khalid University","doi-asserted-by":"publisher","award":["RGP.2 \/557 \/46"],"award-info":[{"award-number":["RGP.2 \/557 \/46"]}],"id":[{"id":"10.13039\/501100023674","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.critrevonc.2026.105144","type":"journal-article","created":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T17:06:53Z","timestamp":1769101613000},"page":"105144","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Innovative approaches to irinotecan-based therapies for glioblastoma: Advancements in drug delivery and combination strategies"],"prefix":"10.1016","volume":"219","author":[{"given":"Chou-Yi","family":"Hsu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirza R.","family":"Baig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pareshkumar N.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunjan","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ihab M.","family":"Abdelrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monthar","family":"Kadhem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vimal","family":"Arora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venkata Ramana","family":"Maddula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya Priyadarshini","family":"Nayak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Shahid","family":"Iqbal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.critrevonc.2026.105144_bib1","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.3923\/ijp.2024.1087.1097","article-title":"To explore the mechanism and experimental verification of brucine inhibition of glioblastoma based on network pharmacology","volume":"20","author":"Xu","year":"2024","journal-title":"Int. J. Pharmacol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105144_bib2","doi-asserted-by":"crossref","first-page":"326","DOI":"10.14744\/ejmo.2023.32728","article-title":"Didymin exhibits different cytotoxicity patterns on U-87 mg human glioblastoma cells and orchestrates the release of substance P (SP) and Interleukin-6 (IL-6) in a time depending manner","volume":"7","author":"Bulut","year":"2023","journal-title":"Eurasia J. Med. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105144_bib3","first-page":"409","article-title":"Cancer treatment and survivorship statistics, 2022","volume":"72","author":"Miller","year":"2022","journal-title":"CA a Cancer J. Clin."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105144_bib4","first-page":"433","article-title":"Efficacy and safety of anlotinib combined with the STUPP regimen in patients with newly diagnosed glioblastoma: a multicenter, single-arm, phase II trial","volume":"21","author":"Lai","year":"2024","journal-title":"Cancer Biol. Med."},{"issue":"23","key":"10.1016\/j.critrevonc.2026.105144_bib5","doi-asserted-by":"crossref","first-page":"7442","DOI":"10.3390\/jcm12237442","article-title":"Temozolomide, procarbazine and nitrosoureas in the therapy of malignant gliomas: update of mechanisms, drug resistance and therapeutic implications","volume":"12","author":"Kaina","year":"2023","journal-title":"J. Clin. Med."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105144_bib6","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s12032-024-02527-x","article-title":"Camptothecin and its derivatives: advancements, mechanisms and clinical potential in cancer therapy","volume":"41","author":"Kamle","year":"2024","journal-title":"Med. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105144_bib7","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1080\/17460441.2022.2055545","article-title":"The design and discovery of topoisomerase I inhibitors as anticancer therapies","volume":"17","author":"Martin-Encinas","year":"2022","journal-title":"Expert Opin. Drug Discov."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105144_bib8","doi-asserted-by":"crossref","first-page":"680","DOI":"10.3390\/cancers16040680","article-title":"Understanding cancer\u2019s defense against topoisomerase-active drugs: a comprehensive review","volume":"16","author":"Sharma","year":"2024","journal-title":"Cancers"},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105144_bib9","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1007\/s11095-023-03590-1","article-title":"Elucidation of carboxylesterase mediated pharmacokinetic interactions between irinotecan and oroxylin A in rats via physiologically based pharmacokinetic modeling: Zhang et al","volume":"40","author":"Zhang","year":"2023","journal-title":"Pharm. Res."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105144_bib10","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.2174\/1389200224666221212143904","article-title":"Covalent CES2 inhibitors protect against reduced formation of intestinal organoids by the anticancer drug irinotecan","volume":"23","author":"Eades","year":"2022","journal-title":"Curr. Drug Metab."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105144_bib11","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/bjc.2011.498","article-title":"Topoisomerase I inhibition in colorectal cancer: biomarkers and therapeutic targets","volume":"106","author":"Gilbert","year":"2012","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105144_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/27694127.2022.2155904","article-title":"Topoisomerase I poisons-induced autophagy: cytoprotective, cytotoxic or non-protective","volume":"2","author":"Elshazly","year":"2023","journal-title":"Autophagy Rep."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105144_bib13","article-title":"Comprehensive metabolomics study identifies SN-38 organ specific toxicity in mice","volume":"15","author":"Zhu","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.critrevonc.2026.105144_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1110460","article-title":"Impact of polymorphisms in CYP and UGT enzymes and ABC and SLCO1B1 transporters on the pharmacokinetics and safety of desvenlafaxine","volume":"14","author":"Calleja","year":"2023","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105144_bib15","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s00228-010-0966-3","article-title":"Do pharmacokinetic polymorphisms explain treatment failure in high-risk patients with neuroblastoma?","volume":"67","author":"Bellanti","year":"2011","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105144_bib16","doi-asserted-by":"crossref","DOI":"10.1002\/ddr.22180","article-title":"A review of natural products and small-molecule therapeutics acting on central nervous system malignancies: approaches for drug development, targeting pathways, clinical trials, and challenges","volume":"85","author":"Pasdaran","year":"2024","journal-title":"Drug Dev. Res."},{"issue":"17","key":"10.1016\/j.critrevonc.2026.105144_bib17","doi-asserted-by":"crossref","first-page":"4279","DOI":"10.3390\/cancers15174279","article-title":"Recurrent glioblastoma: a review of the treatment options","volume":"15","author":"Vaz-Salgado","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2026.105144_bib18","first-page":"1","article-title":"An overview of chemotoxicity and radiation toxicity in cancer therapy","volume":"155","author":"Yazbeck","year":"2022","journal-title":"Adv. Cancer Res."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105144_bib19","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1093\/annonc\/mdy197","article-title":"Temozolomide and irinotecan (TEMIRI regimen) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients bearing MGMT methylation","volume":"29","author":"Morano","year":"2018","journal-title":"Ann. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105144_bib20","first-page":"vi74","article-title":"Exth-09. Tdp1\/top1 ratio as a predictive indicator for the response of glioblastoma cancer cells to irinotecan treatment","volume":"19","author":"Wang","year":"2017","journal-title":"NeuroOncology"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105144_bib21","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s12253-017-0312-5","article-title":"Overexpression of TIMP-1 and sensitivity to topoisomerase inhibitors in glioblastoma cell lines","volume":"25","author":"Aaberg-Jessen","year":"2019","journal-title":"Pathol. Oncol. Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105144_bib22","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s43556-024-00239-2","article-title":"Molecular mechanisms and therapeutic strategies in overcoming chemotherapy resistance in cancer","volume":"6","author":"Gu","year":"2025","journal-title":"Mol. Biomed."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105144_bib23","doi-asserted-by":"crossref","first-page":"849","DOI":"10.3390\/pharmaceutics16070849","article-title":"An overview on the physiopathology of the Blood\u2013Brain barrier and the Lipid-Based nanocarriers for central nervous system delivery","volume":"16","author":"Susa","year":"2024","journal-title":"Pharmaceutics"},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105144_bib24","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1038\/s42256-024-00868-w","article-title":"A transformer-based weakly supervised computational pathology method for clinical-grade diagnosis and molecular marker discovery of gliomas","volume":"6","author":"Jiang","year":"2024","journal-title":"Nat. Mach. Intell."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105144_bib25","doi-asserted-by":"crossref","first-page":"402","DOI":"10.14744\/ejmo.2024.79543","article-title":"Advancements in molecular biomarkers as prognostic predictors for patients with glioblastoma: a systematic review","volume":"8","author":"Aman","year":"2024","journal-title":"Eurasia J. Med. Oncol."},{"issue":"13","key":"10.1016\/j.critrevonc.2026.105144_bib26","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.3390\/cancers15133339","article-title":"Prognostic values of systemic inflammatory immunological markers in glioblastoma: a systematic review and meta-analysis","volume":"15","author":"Jarmuzek","year":"2023","journal-title":"Cancers"},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105144_bib27","doi-asserted-by":"crossref","first-page":"851","DOI":"10.2217\/bmm-2021-0271","article-title":"Neutrophil-to-lymphocyte ratio is prognostic in recurrent glioblastoma multiforme treated with bevacizumab plus irinotecan","volume":"15","author":"Haksoyler","year":"2021","journal-title":"Biomark. Med."},{"key":"10.1016\/j.critrevonc.2026.105144_bib28","doi-asserted-by":"crossref","unstructured":"Korkmaz, M., Ery\u0131lmaz, M.K., Demirk\u0131ran, A., Arta\u00e7, M., 2021. Hemoglobin, albumin, lymphocytes and platelets (HALP) score is a useful predictor of survival in patients with recurrent glioblastoma multiforme treated with bevacizumab plus irinotecan.","DOI":"10.21203\/rs.3.rs-809597\/v2"},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105144_bib29","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.3390\/cancers14102416","article-title":"Alterations in molecular profiles affecting glioblastoma resistance to radiochemotherapy: where does the good go?","volume":"14","author":"Vilar","year":"2022","journal-title":"Cancers"},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105144_bib30","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.3390\/cancers11101416","article-title":"Tyrosyl-DNA phosphodiesterase 1 and topoisomerase I activities as predictive indicators for Glioblastoma susceptibility to genotoxic agents","volume":"11","author":"Wang","year":"2019","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105144_bib31","article-title":"Increased replication stress and R-loop accumulation in EGFRvIII-expressing glioblastoma present new therapeutic opportunities","volume":"4","author":"Struve","year":"2022","journal-title":"NeuroOncol. Adv."},{"key":"10.1016\/j.critrevonc.2026.105144_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.117634","article-title":"The cell cycle inhibitor p21CIP1 is essential for irinotecan-induced senescence and plays a decisive role in re-sensitization of temozolomide-resistant glioblastoma cells to irinotecan","volume":"181","author":"Sallbach","year":"2024","journal-title":"Biomed. Pharmacother."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105144_bib33","first-page":"8","article-title":"A network pharmacology approach to investigate the mechanisms of Huangqin decoction in the treatment of irinotecan-induced gastrointestinal toxicity","volume":"2","author":"Wang","year":"2020","journal-title":"Asian Toxicol. Res."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105144_bib34","doi-asserted-by":"crossref","first-page":"867","DOI":"10.3892\/mmr.2021.12507","article-title":"Knockdown of TRIM9 attenuates irinotecan-induced intestinal mucositis in IEC-6 cells by regulating DUSP6 expression via the P38 pathway","volume":"24","author":"Zhao","year":"2021","journal-title":"Mol. Med. Rep."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105144_bib35","doi-asserted-by":"crossref","first-page":"410","DOI":"10.3390\/curroncol32070410","article-title":"Old tools in a new era: the continued relevance of chemotherapy in pediatric neuro-oncology","volume":"32","author":"Felton","year":"2025","journal-title":"Curr. Oncol."},{"issue":"17","key":"10.1016\/j.critrevonc.2026.105144_bib36","doi-asserted-by":"crossref","first-page":"4279","DOI":"10.3390\/cancers15174279","article-title":"Recurrent glioblastoma: a review of the treatment options","volume":"15","author":"Vaz-Salgado","year":"2023","journal-title":"Cancers"},{"issue":"17","key":"10.1016\/j.critrevonc.2026.105144_bib37","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.3390\/cancers16172975","article-title":"Recent treatment strategies and molecular pathways in resistance mechanisms of antiangiogenic therapies in glioblastoma","volume":"16","author":"Rahman","year":"2024","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105144_bib38","doi-asserted-by":"crossref","first-page":"600","DOI":"10.3390\/cancers14030600","article-title":"Advancements, challenges, and future directions in tackling glioblastoma resistance to small kinase inhibitors","volume":"14","author":"Fabro","year":"2022","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105144_bib39","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.30874","article-title":"A phase 1 study of mebendazole with bevacizumab and irinotecan in high-grade gliomas","volume":"71","author":"Krystal","year":"2024","journal-title":"Pediatr. Blood Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105144_bib40","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s11060-022-03970-4","article-title":"The role of irinotecan-bevacizumab as rescue regimen in children with low-grade gliomas: a retrospective nationwide study in 72 patients","volume":"157","author":"de Marcellus","year":"2022","journal-title":"J. NeuroOncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105144_bib41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4103\/IJNO.IJNO_1_23","article-title":"A retrospective analysis of irinotecan and bevacizumab combination therapy in recurrent high-grade glioma and glioblastoma multiforme: Single-institute experience","volume":"5","author":"Palkonda","year":"2022","journal-title":"Int. J. Neurooncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105144_bib42","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s11060-019-03164-5","article-title":"Cytotoxic synergy between alisertib and carboplatin versus alisertib and irinotecan are inversely dependent on MGMT levels in glioblastoma cells","volume":"143","author":"Sak","year":"2019","journal-title":"J. NeuroOncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105144_bib43","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.32604\/or.2024.052130","article-title":"Hypoxia-inducible factor 1alpha and vascular endothelial growth factor in Glioblastoma Multiforme: a systematic review going beyond pathologic implications","volume":"32","author":"Vageli","year":"2024","journal-title":"Oncol. Res."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105144_bib44","doi-asserted-by":"crossref","first-page":"474","DOI":"10.3390\/ijms26020474","article-title":"Targeting metabolic and epigenetic vulnerabilities in glioblastoma with SN-38 and rabusertib combination therapy","volume":"26","author":"Chiou","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2026.105144_bib45","doi-asserted-by":"crossref","DOI":"10.1017\/erm.2020.3","article-title":"DNA damage checkpoint kinases in cancer","volume":"22","author":"Smith","year":"2020","journal-title":"Expert Rev. Mol. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105144_bib46","article-title":"Unraveling the underlying mechanisms of cancer stem cells in therapeutic resistance for optimizing treatment strategies","volume":"4","author":"Tan","year":"2025","journal-title":"MedCommOncology"},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105144_bib47","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1158\/1078-0432.CCR-19-3470","article-title":"Phase I clinical trial of the Wee1 inhibitor adavosertib (AZD1775) with irinotecan in children with relapsed solid tumors: a COG phase I consortium report (ADVL1312)","volume":"26","author":"Cole","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105144_bib48","author":"DeNardo","year":"2022","journal-title":"Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105144_bib49","first-page":"1","article-title":"Synergistic activity of simvastatin and irinotecan chemotherapy against glioblastoma converges on TGF-\u03b2 signaling","author":"Yadav","year":"2025","journal-title":"J. NeuroOncol."},{"issue":"19","key":"10.1016\/j.critrevonc.2026.105144_bib50","doi-asserted-by":"crossref","first-page":"3300","DOI":"10.3390\/cancers16193300","article-title":"Blood\u2013brain barrier conquest in glioblastoma nanomedicine: strategies, clinical advances, and emerging challenges","volume":"16","author":"Duan","year":"2024","journal-title":"Cancers"},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105144_bib51","doi-asserted-by":"crossref","first-page":"512","DOI":"10.3390\/jpm15110512","article-title":"Leveraging synergy: a review of the therapeutic potential of SN-38 and immune checkpoint blockade in breast and prostate cancer treatment","volume":"15","author":"Adekiya","year":"2025","journal-title":"J. Pers. Med."},{"key":"10.1016\/j.critrevonc.2026.105144_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.inoche.2024.112028","article-title":"Recent advancements in Irinotecan-loaded nanomaterials as a smart drug delivery system for cancer therapy: a state-of-art-review","volume":"161","author":"Fathi-Karkan","year":"2024","journal-title":"Inorg. Chem. Commun."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105144_bib53","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1021\/polymscitech.5c00010","article-title":"Synthetic polymers for drug, gene, and vaccine delivery","volume":"1","author":"Xu","year":"2025","journal-title":"Polym. Sci. Technol."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105144_bib54","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.1007\/s13346-024-01524-x","article-title":"Local administration of irinotecan using an implantable drug delivery device stops high-grade glioma tumor recurrence in a glioblastoma tumor model","volume":"14","author":"Abdelnabi","year":"2024","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.critrevonc.2026.105144_bib55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2020.05.012","article-title":"Development and in vivo evaluation of Irinotecan-loaded Drug Eluting Seeds (iDES) for the localised treatment of recurrent glioblastoma multiforme","volume":"324","author":"Gawley","year":"2020","journal-title":"J. Control Release"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105144_bib56","doi-asserted-by":"crossref","first-page":"479","DOI":"10.3390\/pharmaceutics12050479","article-title":"Injectable SN-38-embedded polymeric microparticles promote antitumor efficacy against malignant glioma in an animal model","volume":"12","author":"Tseng","year":"2020","journal-title":"Pharmaceutics"},{"issue":"14","key":"10.1016\/j.critrevonc.2026.105144_bib57","doi-asserted-by":"crossref","first-page":"3510","DOI":"10.3390\/ma17143510","article-title":"Novel Collagen Membrane Formulations with Irinotecan or Minocycline for Potential Application in Brain Cancer","volume":"17","author":"Idu","year":"2024","journal-title":"Materials"},{"issue":"19","key":"10.1016\/j.critrevonc.2026.105144_bib58","doi-asserted-by":"crossref","first-page":"7111","DOI":"10.3390\/ijms21197111","article-title":"Injectable thermo-sensitive chitosan hydrogel containing CPT-11-loaded EGFR-targeted graphene oxide and SLP2 shRNA for localized drug\/gene delivery in glioblastoma therapy","volume":"21","author":"Lu","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"20","key":"10.1016\/j.critrevonc.2026.105144_bib59","doi-asserted-by":"crossref","first-page":"11271","DOI":"10.3390\/ijms252011271","article-title":"Status Quo in the Liposome-Based Therapeutic Strategies Against Glioblastoma:\u201cTargeting the Tumor and Tumor Microenvironment","volume":"25","author":"Haseeb","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"19","key":"10.1016\/j.critrevonc.2026.105144_bib60","doi-asserted-by":"crossref","first-page":"4960","DOI":"10.3390\/cancers14194960","article-title":"Advances in Preclinical\/Clinical Glioblastoma Treatment: Can Nanoparticles Be of Help?","volume":"14","author":"Ruiz-Molina","year":"2022","journal-title":"Cancers"},{"issue":"14","key":"10.1016\/j.critrevonc.2026.105144_bib61","article-title":"Targeted Delivery of DNA Topoisomerase Inhibitor SN38 to Intracranial Tumors of Glioblastoma Using Sub-5 Ultrafine Iron Oxide Nanoparticles","volume":"11","author":"Li","year":"2022","journal-title":"Adv. Healthc. Mater."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105144_bib62","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-64186-2","article-title":"PLX038A, a long-acting SN-38, penetrates the blood-tumor-brain-barrier, accumulates and releases SN-38 in brain tumors to increase survival of tumor bearing mice","volume":"14","author":"Jung","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.critrevonc.2026.105144_bib63","article-title":"A phase I study of convection-enhanced delivery (CED) of liposomal-irinotecan using real-time imaging with gadolinium in patients with recurrent high grade glioma","volume":"10","author":"Butowski","year":"2022","journal-title":"Brain Tumor Res. Treat."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105144_bib64","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s11060-017-2681-8","article-title":"New therapeutic approaches for brainstem tumors: a comparison of delivery routes using nanoliposomal irinotecan in an animal model","volume":"136","author":"Louis","year":"2018","journal-title":"J. NeuroOncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105144_bib65","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s11095-017-2278-0","article-title":"Liposomal irinotecan accumulates in metastatic lesions, crosses the blood-tumor barrier (BTB), and prolongs survival in an experimental model of brain metastases of triple negative breast cancer","volume":"35","author":"Mohammad","year":"2018","journal-title":"Pharm. Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105144_bib66","doi-asserted-by":"crossref","first-page":"6707","DOI":"10.1038\/s41467-024-50558-9","article-title":"Sacituzumab Govitecan in patients with breast cancer brain metastases and recurrent glioblastoma: a phase 0 window-of-opportunity trial","volume":"15","author":"Balinda","year":"2024","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105144_bib67","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1186\/s12951-022-01610-7","article-title":"Overcoming the blood\u2013brain barrier for the therapy of malignant brain tumor: current status and prospects of drug delivery approaches","volume":"20","author":"Mitusova","year":"2022","journal-title":"J. Nanobiotechnol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105144_bib68","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1021\/acsomega.3c07486","article-title":"Development of a targeted SN-38-conjugate for the treatment of glioblastoma","volume":"9","author":"Bataille Backer","year":"2024","journal-title":"ACS Omega"},{"key":"10.1016\/j.critrevonc.2026.105144_bib69","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1129627","article-title":"Clinically relevant glioblastoma patient-derived xenograft models to guide drug development and identify molecular signatures","volume":"13","author":"Alcaniz","year":"2023","journal-title":"Front. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105144_bib70","doi-asserted-by":"crossref","first-page":"399","DOI":"10.3390\/pharmaceutics12050399","article-title":"Characterization of the blood\u2013brain barrier integrity and the brain transport of SN-38 in an orthotopic xenograft rat model of diffuse intrinsic pontine glioma","volume":"12","author":"Chaves","year":"2020","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105144_bib71","doi-asserted-by":"crossref","first-page":"8766","DOI":"10.1038\/s41598-020-65617-6","article-title":"Blood-brain barrier disruption and delivery of irinotecan in a rat model using a clinical transcranial MRI-guided focused ultrasound system","volume":"10","author":"McDannold","year":"2020","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105144_bib72","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/s41392-025-02299-4","article-title":"Glioblastoma at the crossroads: current understanding and future therapeutic horizons","volume":"10","author":"Singh","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105144_bib73","first-page":"4","article-title":"Drug resistance in glioblastoma: challenges, mechanisms and therapeutic strategies (Review)","volume":"24","author":"Durga","year":"2026","journal-title":"Mol. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105144_bib74","doi-asserted-by":"crossref","DOI":"10.3390\/brainsci15080833","article-title":"Unraveling glioblastoma heterogeneity: advancing immunological insights and therapeutic innovations","volume":"15","author":"Liu","year":"2025","journal-title":"Brain Sci."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105144_bib75","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1007\/s12032-024-02501-7","article-title":"The role of molecular biomarkers in recurrent glioblastoma trials: an assessment of the current trial landscape of genome-driven oncology","volume":"41","author":"van Opijnen","year":"2024","journal-title":"Med. Oncol."},{"issue":"14","key":"10.1016\/j.critrevonc.2026.105144_bib76","doi-asserted-by":"crossref","first-page":"7974","DOI":"10.3390\/ijms25147974","article-title":"Circulating liquid biopsy biomarkers in glioblastoma: advances and challenges","volume":"25","author":"Seyhan","year":"2024","journal-title":"Int. J. Mol. Sci. [Internet]"},{"issue":"34","key":"10.1016\/j.critrevonc.2026.105144_bib77","doi-asserted-by":"crossref","DOI":"10.3346\/jkms.2024.39.e244","article-title":"Bevacizumab alone versus bevacizumab plus irinotecan in patients with recurrent glioblastoma: a nationwide population-based study","volume":"39","author":"Lee","year":"2024","journal-title":"J. Korean Med Sci."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105144_bib78","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1158\/1078-0432.CCR-19-3470","article-title":"Phase I clinical trial of the Wee1 Inhibitor Adavosertib (AZD1775) with irinotecan in children with relapsed solid tumors: a COG phase i consortium report (ADVL1312)","volume":"26","author":"Cole","year":"2020","journal-title":"Clin. Cancer Res"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105144_bib79","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17040701","article-title":"Progress in drug delivery systems based on nanoparticles for improved glioblastoma therapy: addressing challenges and investigating opportunities","volume":"17","author":"Rahman","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.critrevonc.2026.105144_bib80","doi-asserted-by":"crossref","first-page":"9597","DOI":"10.2147\/IJN.S531451","article-title":"Advances and challenges in nano-delivery systems for glioblastoma treatment: a comprehensive review","volume":"20","author":"Wang","year":"2025","journal-title":"Int. J. Nanomed."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105144_bib81","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/s41568-024-00706-6","article-title":"Cancer organoids 2.0: modelling the complexity of the tumour immune microenvironment","volume":"24","author":"Polak","year":"2024","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105144_bib82","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-64186-2","article-title":"PLX038A, a long-acting SN-38, penetrates the blood-tumor-brain-barrier, accumulates and releases SN-38 in brain tumors to increase survival of tumor bearing mice","volume":"14","author":"Jung","year":"2024","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105144_bib83","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1021\/acsomega.3c07486","article-title":"Development of a targeted SN-38-conjugate for the treatment of glioblastoma","volume":"9","author":"Bataille Backer","year":"2024","journal-title":"ACS Omega"},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105144_bib84","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics17060732","article-title":"Synthesis and characterization of transferrin receptor-targeted peptide combination SN-38 and rucaparib conjugate for the treatment of glioblastoma","volume":"17","author":"Bataille Backer","year":"2025","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105144_bib85","article-title":"Self-assembling polypeptide-drug conjugates as innovative therapeutic candidates for glioblastoma treatment by enhancing intracranial residence time","volume":"7","author":"Gwon","year":"2025","journal-title":"NeuroOncol. Adv."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105144_bib86","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26020474","article-title":"Targeting metabolic and epigenetic vulnerabilities in glioblastoma with SN-38 and rabusertib combination therapy","volume":"26","author":"Chiou","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2026.105144_bib87","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.117634","article-title":"The cell cycle inhibitor p21(CIP1) is essential for irinotecan-induced senescence and plays a decisive role in re-sensitization of temozolomide-resistant glioblastoma cells to irinotecan","volume":"181","author":"Sallbach","year":"2024","journal-title":"Biomed. Pharm."},{"key":"10.1016\/j.critrevonc.2026.105144_bib88","article-title":"Multivoid magnetic nanoparticles as high-performance magnetic particle imaging tracers for precise glioma detection","author":"Liang","year":"2025","journal-title":"Bioconjugate Chem."},{"issue":"17","key":"10.1016\/j.critrevonc.2026.105144_bib89","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16173008","article-title":"Local delivery of irinotecan to recurrent GBM patients at reoperation offers a safe route of administration","volume":"16","author":"McConville","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105144_bib90","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s11060-024-04904-y","article-title":"A phase I study of convection-enhanced delivery (CED) of liposomal-irinotecan using real-time magnetic resonance imaging in patients with recurrent high-grade glioma","volume":"172","author":"Narsinh","year":"2025","journal-title":"J. Neurooncol."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826000314?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826000314?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T12:49:50Z","timestamp":1774010990000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826000314"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":90,"alternative-id":["S1040842826000314"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105144","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Innovative approaches to irinotecan-based therapies for glioblastoma: Advancements in drug delivery and combination strategies","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105144","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105144"}}